Glaucoma, Open-Angle
Recent clinical, regulatory, research and industry developments relating to this disease.
European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition.
Inflammation in Glaucoma: From the back to the front of the eye, and beyond.
The number of people with glaucoma worldwide in 2010 and 2020.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Phase 2 Randomized, Multi-center, Parallel, Active-controlled Clinical Study to Evaluate the Safety and Efficacy of Intracameral PA5108 Ocular Implants in Patients With Primary Open-angle Glaucoma, or Ocular Hypertension
- Q2 2027Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular Hypertension
Clinical MilestonesViewHide
- 2026-07-08A Phase 2 Randomized, Multi-center, Parallel, Active-controlled Clinical Study to Evaluate the Safety and Efficacy of Intracameral PA5108 Ocular Implants in Patients With Primary Open-angle Glaucoma, or Ocular HypertensionResults expected Q4 2026
- 2026-06-02Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular HypertensionResults expected Q2 2027
- 2026-07-08ClinicalA Phase 2 Randomized, Multi-center, Parallel, Active-controlled Clinical Study to Evaluate the Safety and Efficacy of Intracameral PA5108 Ocular Implants in Patients With Primary Open-angle Glaucoma, or Ocular HypertensionResults expected Q4 2026
- 2026-06-02ClinicalMulticenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With the Placement of iStent Infinite in Subjects With Open-angle Glaucoma or Ocular HypertensionResults expected Q2 2027
- 2026-04-01ClinicalA Phase III Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle GlaucomaPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult… (2023)
Approval — Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angl… (2019)
Approval — Decrease of elevated intraocular pressure in adult patients with ocular hypertension or o… (2014)
Approval — Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hype… (2002)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Glaucoma4
- Glaucoma, Open-Angle4
- Glaucoma, Angle-Closure1
- Global Health1
Leading journals4
- Nature communications2
- The British journal of ophthalmology2
- Lancet (London, England)1
- Progress in retinal and eye research1
Leading researchers8
- Gharahkhani P2
- Hamel AR2
- Khawaja AP2
- Kolko M2
- MacGregor S2
- Pasquale LR2
- Rouhana JM2
- Segrè AV2
Affiliations (unnormalised)6
- Harvard Medical School2
- Icahn School of Medicine at Mount Sinai2
- NIHR Biomedical Research Centre2
- QIMR Berghofer Medical Research Institute2
- Baylor College of Medicine1
- Biomedical and Translational Informatics Institute1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Open-angle glaucoma is a form of glaucoma in which the anterior chamber angle remains open and the trabecular meshwork does not encroach on the base of the iris. It is a common cause of irreversible sight loss and is characterized by progressive loss of retinal ganglion cells.
The supplied grounding supports a heritable contribution to primary open-angle glaucoma, with genome-wide studies identifying many risk loci across ancestries. It also indicates that the disease is multifactorial and not completely understood, with genetic factors contributing to pathogenesis.
The literature describes glaucoma as a progressive neurodegenerative process involving retinal ganglion cell loss and optic nerve damage. Elevated intraocular pressure and/or impaired retinal blood flow may initiate injury, while oxidative stress, mitochondrial dysfunction, excitotoxicity, neuroinflammation, and trabecular meshwork dysfunction are implicated in progression and in elevated intraocular pressure.
Elevated intraocular pressure is the only modifiable risk factor supported by large clinical trials, although it is not always present. The disease is also associated with age-related oxidative stress and a heritable genetic predisposition, including multiple risk loci identified in genome-wide studies.
Treatment is generally directed at lowering intraocular pressure. The main modalities described are topical medications, laser treatments, and surgery, including newer minimally invasive surgical approaches.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.